

CLEAN VERSION OF THE AMENDMENTS

In the Specification:

Please substitute the attached specification in compliance with 37 CFR 1/125 (b). The attached substitute specification does not contain any new matter. Please note that the title of the invention is also amended.

In the Drawings:

Submitted for the Examiner's approval, the amendments to Figure 1 are shown in red in compliance with 37 CFR 1.121(d).

In compliance with 37 CFR 1.85 submitted are corrected Figures 2, 3 and 4.

In the Claims:

Please cancel Claims 5, 13, 14, 17-26 and 28.

Please rewrite Claim 1-4; 6-12, 15, 16, and 27 as follows:

1. (Once Amended) A composition comprising a pharmaceutically acceptable carrier, a deglycosylated kringle 1-3 region fragment of a plasminogen protein, and, optionally, a naturally glycosylated kringle 1-3 region fragment of a plasminogen protein, wherein the deglycosylated kringle 1-3 region fragment lacks one or more carbohydrate moieties linked to naturally glycosylated forms of the fragment, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity, and wherein a naturally glycosylated kringle 1-3 region fragment, when present, is in a smaller amount than deglycosylated kringle 1-3 region fragment.

2. (Once amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks a bisialylated-biantennary glycan.

3. (Once amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks an N-linked carbohydrate moiety.

B¹
cont
4. (Once amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment lacks a carbohydrate chain at amino acid position corresponding to the N-glycosylation site of human plasminogen.

6. (Once amended) The composition of claim 5, wherein the deglycosylated kringle 1-3 region fragment begins at approximately amino acid 87 of human plasminogen.

Orb
C2
7. (Once amended) The composition of claim 5, wherein the deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.

B²
8. (Once amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment is produced recombinantly.

9. (Once amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has an amino acid substitution at amino acid position corresponding to the N-glycosylation site of human plasminogen.

10. (Once amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment and the glycosylated form of the fragment are at a ratio of at least 60:40.

11. (Once amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment and the glycosylated form of the fragment are at a ratio of at least 80:20.

12. (Once amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment and the glycosylated form of the fragment are at a ratio of 100:0.

15. (Once amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vitro*.

B3
16. (Once amended) The composition of claim 1, wherein the deglycosylated kringle 1-3 region fragment has antiangiogenic activity *in vivo*.

B4
27. (Once amended) A deglycosylated kringle region kringle 1-3 region fragment of a plasminogen protein, wherein the deglycosylated kringle 1-3 region fragment amino acid sequence is shown in SEQ ID NO:2.
